EGFR and colorectal carcinoma: There is mounting evidence supporting EGFR ligands, which are overexpressed in CRC, with potential key roles in tumour progression, as predictive biomarkers for EGFR-targeted therapy sensitivity, as well as mediators of therapy resistance, reviewed in more detail by Guernsey–Biddle and colleagues [223].